Full-Time

Medical Science Liaison

Msl

Posted on 2/28/2025

Syndax

Syndax

201-500 employees

Develops cancer therapies and conducts clinical trials

Compensation Overview

$225k - $258k/yr

+ Equity Offering + Annual Target Bonuses

Senior

New York, NY, USA

Candidates must be based in the Northeast region, particularly New York, NY.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Syndax referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Advanced Degree such as MD, PhD, PharmD, NP/PA required.
  • 5+ years of MSL, Medical Affairs, or Clinical Development experience within Oncology – required.
  • Existing relationships with institutions, practices, and/or hospitals in territory -required.
  • Strong broad-based scientific and pharmaceutical knowledge.
  • Proven experience as a Principal / Lead Oncology MSL, leading large-scale projects with significant impact on company objectives, demonstrating successful execution of strategic initiatives in HCP engagement, clinical research, and field excellence.
  • Skilled in driving cross-functional collaboration, delivering high-quality scientific insights, and consistently achieving measurable outcomes aligned with corporate goals.
  • Exceptional organizational and time management skills.
  • Strong interpersonal skills including excellent collaboration, verbal and written communication.
  • Computer proficiency in Excel, Word, PowerPoint, and Adobe®.
  • Ability to travel frequently (50-70%), including overnight travel.
Responsibilities
  • Develop and foster strong scientific relationships with Key Opinion Leaders (KOLs), disease experts, and other health care providers (HCPs).
  • Engage in peer-to-peer scientific exchange of complex clinical and scientific data and information.
  • Act as a primary point of contact to address scientific inquiries and deliver presentations on disease state, mechanisms of action, and clinical data, and serve as the scientific expert in support of Syndax therapeutic areas of interest.
  • Identify and evaluate Key Opinion Leaders (KOLs) and profile key institutions aligned with the medical strategy.
  • Create and maintain a strategic territory plan in developing and maintaining KOL relationships for Syndax.
  • Gather, analyze, and communicate actionable insights from the field to inform company strategy, including competitive intelligence, clinical challenges, and patient management trends.
  • Participate in and contribute to cross-functional insight forums, ensuring insights from the field are shared and discussed with Medical Affairs, R&D, and other key internal stakeholders.
  • Support evidence generation activities to identify and address data gaps within the medical strategy.
  • Engage and collaborate with clinical development on clinical trial site identification and support for future and ongoing clinical trials.
  • Support company-sponsored clinical trials and investigator-sponsored trials (IST) by identifying trial sites, providing scientific input, and facilitating partnerships with investigators.
  • Serve as a subject matter expert to support clinical trial education and enrollment initiatives.
  • Represent the company at key medical congresses and scientific meetings, engaging in scientific exchange, gathering insights, and supporting congress activities.
  • Partner with Medical Affairs to plan and execute advisory boards and other scientific activities, contributing to agenda setting, scientific content development, and post-meeting follow-up.
  • Document all field activities in Veeva CRM in accordance with company policies and regulatory requirements, ensuring compliance with industry standards.
  • Act as a mentor to junior MSLs and provide training on best practices in scientific exchange, insight generation, and territory planning.
  • Contribute to territory planning, establishing objectives that support broader organizational goals and metrics for field excellence.
Desired Qualifications
  • Strong preference to medical affairs experience in Oncology.

Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in trials with Exemestane for treating HR+, HER2- breast cancer, and the outcomes of these trials are vital for the company's growth. Unlike many competitors, Syndax emphasizes targeting underserved patient populations and may also form partnerships with other pharmaceutical companies to enhance its market reach. The goal of Syndax is to advance cancer treatment through the development of new therapies and to support its operations through strategic capital raises.

Company Size

201-500

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of Niktimvoâ„¢ highlights Syndax's success in innovative cancer therapy development.
  • Positive trial results for Revuforj® indicate strong potential in acute leukemia treatment.
  • Stifel Financial's investment shows confidence in Syndax's innovative cancer therapy pipeline.

What critics are saying

  • Potential legal challenges from fiduciary duty breaches could impact Syndax's financial stability.
  • Pressure to meet sales projections for Niktimvoâ„¢ could affect Syndax's market performance.
  • Shareholder dissatisfaction may arise from inducement grants perceived as excessive.

What makes Syndax unique

  • Syndax focuses on innovative cancer therapies targeting specific receptors like CSF-1R.
  • The company develops combination therapies, enhancing treatment outcomes for difficult-to-treat cancers.
  • Syndax's pipeline includes unique drugs like Entinostat and Revuforj® for targeted cancer treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 9%

2 year growth

↑ 9%
The Manila Times
Apr 2nd, 2025
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax announces participation at the Stifel 2025 Virtual Targeted Oncology Forum.

PR Newswire
Jan 30th, 2025
Syndax Announces Participation In February Investor Conferences

WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025 , at 10:30 a.m. ETin with a fireside chat on , at Citi's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025 , at 9:00 a.m. ETA live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor

PR Newswire
Jan 15th, 2025
Incyte And Syndax Announce U.S. Food And Drug Administration (Fda) Approval Of Niktimvoâ„¢ (Axatilimab-Csfr) 9 Mg And 22 Mg Vial Sizes

– U.S. launch expected in early February –– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis –– Pivotal data from the AGAVE-201 trial supporting FDA approval show treatment with Niktimvo resulted in durable responses across all organs studied and patient subgroups –WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S

Stock Titan
Jan 7th, 2025
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Syndax announces presentation at 43rd Annual J.P. Morgan Healthcare Conference.

PR Newswire
Jan 3rd, 2025
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.Syndax ContactSharon KlahreSyndax Pharmaceuticals, Inc.[email protected]Tel 781.684.9827SOURCE Syndax Pharmaceuticals, Inc

INACTIVE